Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults

Abstract

This post hoc analysis of the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) showed significant and persistent efficacy of PCV13 against VT-CAP in at-risk older adults. ClinicalTrials.gov identifier: NCT00744263.

Vacunación neumocócica conjugada en adultos. Recomendaciones de las Sociedades Médicas en México

“…El concepto de inmunosenescencia se define como «los cambios que reducen la protección de las vacunas como resultado del envejecimiento y los efectos de éste sobre las in-NCT www.medigraphic.org.mx Tabla 1: Diferencias entre PCV13 y PPSV23. [15][16][17][18][19][20]…”

“…El estudio CAPiTA también demostró www.medigraphic.org.mx que la vacuna PCV13 provocaba no sólo aumentos significativos y duraderos en los títulos de la actividad opsonofagocítica (OPA, por sus siglas en inglés) sino también en las concentraciones de inmunoglobulina G para los 13 serotipos, lo que pone en evidencia la actividad inmunogénica de la vacuna PCV13 en adultos con y sin condiciones médicas crónicas subyacentes y que, inclusive, dada la eficacia contra VT-CAP en adultos mayores en riesgo, su uso puede extenderse a adultos en riesgo menores de 65 años. 20 Las estrategias de inmunización contra el neumococo varían con respecto a los grupos de edad, los grupos de riesgo y el tipo de vacuna utilizada (PPSV23, PCV13 o ambas). De acuerdo con la evidencia epidemiológica disponible, la mejor estrategia de inmunización antineumocócica para reducir la carga de infecciones de vías respiratorias bajas debe sustentarse en la edad y en los factores de riesgo.…”

Pneumococcal Vaccine as One of the Immunization Coverage Targets For Adulthood Vaccines: A Consensus Report of the Study Group For Adult Immunization of the Turkish Society of Clinical Microbiology and Infectious Diseases

“…Kalp, akciğer ve karaciğer hastalığı, astım ve tütün kullanımı gibi kronik sağlık sorunları nedeniyle risk altındaki yaşlı erişkin popülasyonda, KPA13'ün aşıdaki serotiplere bağlı TGP'ye karşı anlamlı ve sürekli bir aşı etkinliği olduğu gösterilmiştir. (80).…”

Paediatric and adult bronchiectasis: Vaccination in prevention and management

“…Preventing severe bacterial pneumonia in children may reduce the risk of bronchiectasis in children and adults, while in those with established bronchiectasis preventing lower airway infection and pneumonia may minimise further lung damage and premature mortality . A post hoc analysis of the efficacy of the 13‐valent PCV in over 40 000 adults in the Netherlands at high risk of community‐acquired pneumonia (CAP), including those with chronic lung disease, demonstrated a vaccine efficacy of 40.3% (95.2% CI: 11.4%–60.2%) against the first episode of vaccine‐type CAP with an average follow‐up duration of 3.95 years. Chronic lung disease (self‐reported) was present in approximately 20% of the study population, and the analyses were not undertaken specifically in this group.…”

“…A post hoc analysis of the efficacy of the 13‐valent PCV in over 40 000 adults in the Netherlands at high risk of community‐acquired pneumonia (CAP), including those with chronic lung disease, demonstrated a vaccine efficacy of 40.3% (95.2% CI: 11.4%–60.2%) against the first episode of vaccine‐type CAP with an average follow‐up duration of 3.95 years. Chronic lung disease (self‐reported) was present in approximately 20% of the study population, and the analyses were not undertaken specifically in this group. Another post hoc analysis of data from three studies of the 13‐valent PCV in immunocompetent adults aged ≥50 years with stable underlying medical conditions (including chronic lung disease) reported robust functional antibody responses in the risk group that were comparable to those not at risk .…”